Company Overview of PharmAbcine, Inc.
PharmAbcine, Inc., a biotech company, develops and provides human therapeutic monoclonal antibody for the treatment of cancer and inflammatory diseases. The company provides TTAC-0001, a human anti-angiogenic monoclonal antibody against VEGFR-2(KDR); and DIG-body and PIG-body that are dual specific monoclonal antibody technologies for therapeutic use. It also offers antibody panning services. The company was founded in 2008 and is based in Daejeon, South Korea.
461-8, Daejeon BioventureTown
Founded in 2008
82 4 2863 2017
82 4 2863 2080
Key Executives for PharmAbcine, Inc.
PharmAbcine, Inc. Key Developments
Similar Private Companies By Industry
|Wyeth Korea Inc.||Asia|
|Hanseo Chemical Co., Ltd.||Asia|
|Samsung Bioepis Co., Ltd.||Asia|
|BIOTRION Co., Ltd.||Asia|
|Mettler-Toledo (Korea) Ltd.||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Germany, PA | Life TechnologiesPosted: Nov 22
- Spring House, PA | Johnson & JohnsonPosted: Dec 05
- Houston, TX | Baylor College of MedicinePosted: Dec 07
- Frederick, MD | Computer Sciences Corporation (CSC)Posted: Dec 01
Sponsored Financial Commentaries
To contact PharmAbcine, Inc., please visit www.pharmabcine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.